首页 > 最新文献

Cancer Radiotherapie最新文献

英文 中文
Issue Contents 议题内容
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1016/S1278-3218(24)00107-0
{"title":"Issue Contents","authors":"","doi":"10.1016/S1278-3218(24)00107-0","DOIUrl":"10.1016/S1278-3218(24)00107-0","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 4","pages":"Pages e7-e8"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1278321824001070/pdfft?md5=3edf77553164a30440dedb34b20e91b0&pid=1-s2.0-S1278321824001070-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142099069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Étude prospective longitudinale sur l’évolution de la mémoire autobiographique de patients irradiés pour une tumeur bénigne de la base du crâne [良性颅底肿瘤照射患者自传体记忆演变的前瞻性纵向研究]。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1016/j.canrad.2023.11.003

Purpose

Cranial irradiation can lead to long-term neurological complications, in particular memory disorders. The aim of this prospective study is to evaluate the impact of irradiation of benign skull base tumours located near the hippocampi on autobiographical memory.

Patients and methods

From 2016 to 2019, patients with cavernous sinus meningioma or pituitary adenoma treated with normofractionated irradiation were included. Patients underwent full neuropsychological assessment at baseline, 1 year and 2 years post-treatment. Neuropsychological tests were converted to Z-Score for comparability.

Results

Twelve of the 19 patients included had a complete neuropsychological evaluation at 2 years and were analysed. On the “TEMPau” test, no significant difference in autobiographical memory was found at 2 years, regardless of the period of autobiographical memory. The mean hippocampal dose had no impact on the variation in autobiographical memory. There was no significant cognitive impairment in the other domains assessed, such as attention, anterograde memory, working memory and executive functions. Autobiographical memory was independent of these other cognitive domains, which justifies its specific study.

Conclusion

Radiotherapy to the skull base for a benign pathology does not lead to significant cognitive impairment. Longer follow-up would be needed to confirm these results.

目的:颅骨照射可导致长期的神经系统并发症,尤其是记忆障碍。本前瞻性研究旨在评估位于海马附近的良性颅底肿瘤照射对自传体记忆的影响:从2016年至2019年,纳入了接受正常分次照射治疗的海绵窦脑膜瘤或垂体腺瘤患者。患者在基线、治疗后1年和2年接受了全面的神经心理学评估。为便于比较,神经心理测试结果被转换成Z-分数:在 19 名患者中,有 12 人在治疗后 2 年接受了完整的神经心理学评估,并对其进行了分析。在 "TEMPau "测试中,无论自传体记忆的时间长短,2 年后的自传体记忆均无明显差异。海马平均剂量对自传体记忆的变化没有影响。在其他评估领域,如注意力、前向记忆、工作记忆和执行功能等,没有发现明显的认知障碍。自传体记忆与其他认知领域无关,因此有必要对其进行专门研究:结论:针对良性病变的颅底放疗不会导致明显的认知障碍。要证实这些结果,还需要更长时间的随访。
{"title":"Étude prospective longitudinale sur l’évolution de la mémoire autobiographique de patients irradiés pour une tumeur bénigne de la base du crâne","authors":"","doi":"10.1016/j.canrad.2023.11.003","DOIUrl":"10.1016/j.canrad.2023.11.003","url":null,"abstract":"<div><h3>Purpose</h3><p>Cranial irradiation can lead to long-term neurological complications, in particular memory disorders. The aim of this prospective study is to evaluate the impact of irradiation of benign skull base tumours located near the hippocampi on autobiographical memory.</p></div><div><h3>Patients and methods</h3><p>From 2016 to 2019, patients with cavernous sinus meningioma or pituitary adenoma treated with normofractionated irradiation were included. Patients underwent full neuropsychological assessment at baseline, 1<!--> <!-->year and 2<!--> <!-->years post-treatment. Neuropsychological tests were converted to <em>Z-Score</em> for comparability.</p></div><div><h3>Results</h3><p>Twelve of the 19 patients included had a complete neuropsychological evaluation at 2<!--> <!-->years and were analysed. On the “TEMPau” test, no significant difference in autobiographical memory was found at 2<!--> <!-->years, regardless of the period of autobiographical memory. The mean hippocampal dose had no impact on the variation in autobiographical memory. There was no significant cognitive impairment in the other domains assessed, such as attention, anterograde memory, working memory and executive functions. Autobiographical memory was independent of these other cognitive domains, which justifies its specific study.</p></div><div><h3>Conclusion</h3><p>Radiotherapy to the skull base for a benign pathology does not lead to significant cognitive impairment. Longer follow-up would be needed to confirm these results.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 4","pages":"Pages 309-316"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nuclear protein in testis (NUT) midline carcinoma of the larynx: A rare case report of a paediatric patient and literature review 睾丸核蛋白(NUT)喉中线癌:一例罕见的儿科患者病例报告和文献综述。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1016/j.canrad.2024.02.004
G. Ugurluer , N. Dincer , A.E. Danyeli , L. Celik , A.L. Guner , F. Corapcioglu , C. Canpolat , Y.B. Kok , E. Ozyar

Nuclear protein in testis (NUT) carcinoma is a rare neoplasm arising mainly from midline structures. It is an aggressive type of carcinoma associated with poor survival despite the use of multiple treatment modalities. Here, we present a case of a 17-year-old paediatric patient with NUT carcinoma of larynx, which is even rarer among all reported cases. The patient underwent surgery followed by radiotherapy and systemic treatment and he died 15 months after the diagnosis. The management of this rare disease requires further investigation.

睾丸核蛋白癌(NUT)是一种罕见的肿瘤,主要发生于中线结构。它是一种侵袭性癌,尽管采用了多种治疗方法,但患者的生存率很低。在这里,我们介绍了一例 17 岁儿童喉 NUT 癌患者的病例,这在所有报道的病例中更为罕见。患者接受了手术、放疗和全身治疗,确诊后 15 个月死亡。这种罕见疾病的治疗需要进一步研究。
{"title":"Nuclear protein in testis (NUT) midline carcinoma of the larynx: A rare case report of a paediatric patient and literature review","authors":"G. Ugurluer ,&nbsp;N. Dincer ,&nbsp;A.E. Danyeli ,&nbsp;L. Celik ,&nbsp;A.L. Guner ,&nbsp;F. Corapcioglu ,&nbsp;C. Canpolat ,&nbsp;Y.B. Kok ,&nbsp;E. Ozyar","doi":"10.1016/j.canrad.2024.02.004","DOIUrl":"10.1016/j.canrad.2024.02.004","url":null,"abstract":"<div><p><span>Nuclear protein in testis (NUT) carcinoma is a rare neoplasm arising mainly from midline structures. It is an aggressive type of carcinoma associated with poor survival despite the use of multiple treatment modalities. Here, we present a case of a 17-year-old paediatric patient with NUT carcinoma of </span>larynx, which is even rarer among all reported cases. The patient underwent surgery followed by radiotherapy and systemic treatment and he died 15 months after the diagnosis. The management of this rare disease requires further investigation.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 4","pages":"Pages 385-389"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Voice quality after surgery or radiotherapy for glottic T1 squamous cell carcinoma: Results of the VOQUAL study 声门 T1 鳞状细胞癌手术或放疗后的嗓音质量:VOQUAL 研究结果
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1016/j.canrad.2024.03.004
J. Louison , J. Labreuche , X. Liem , B. Rysman , M. Morisse , G. Mortuaire , F. Mouawad

Purpose

Many series have compared voice quality after radiotherapy or surgery for cT1 glottic carcinoma. Different meta-analyses identify better results for radiotherapy while others do not identify any difference, some finally find a superiority of surgery. The purpose of this study was to compare the voice quality in the long term of patients who underwent transoral surgery versus exclusive irradiation for the treatment of cT1 glottic carcinoma.

Material and methods

The VOQUAL study was a pilot comparative multicenter cross-sectional study. The primary endpoint was the Voice Handicap Index comparison between two groups (radiotherapy or surgery). The voice assessment also consisted in the heteroevaluation of voice quality by the Grade, Roughness, Breathness, Asthenia, and Strain rating scale reported by Hirano.

Results

The study included 41 adult patients with cT1 carcinoma of the vocal cord treated by cordectomy or exclusive radiation in two oncologic centers. The median Voice Handicap Index value was 20 [8; 32.5] in the surgery group and 10 [4; 18.5] in the radiotherapy group. There was no statistically significant difference between the median values and the various components F, P and E of the questionnaire (P = 0.1585). The median value of the numeric dysphonia Grade, Roughness, Breathness, Asthenia, and Strain scale was 2 [0; 5] in the surgery group and 2 [0.25; 3.75] in the radiotherapy group. There was no statistically significant difference between these values (P = 0.78).

Conclusion

Our study did not show any significant difference on the primary endpoints of Voice Handicap Index and Grade, Roughness, Breathness, Asthenia, and Strain scores.

Level of evidence

III. Clinical trial registration: The VOQUAL study was registered on the ClinicalTrials.gov platform under the number NCT04447456, in July 2020.

目的:许多研究对 cT1 声门癌放疗或手术后的语音质量进行了比较。不同的荟萃分析结果表明,放疗的效果更好,而其他荟萃分析结果则没有发现任何差异。本研究的目的是比较经口手术与单纯照射治疗 cT1 声门癌患者的长期嗓音质量:VOQUAL 研究是一项试验性多中心横断面比较研究。主要终点是两组(放疗或手术)之间的嗓音障碍指数比较。嗓音评估还包括通过平野报告的等级、粗糙度、呼吸度、气喘和应变评分表对嗓音质量进行异质评估:研究对象包括两个肿瘤中心的 41 名 cT1 声带癌成人患者,他们都接受了声带切除术或单纯放射治疗。手术组嗓音障碍指数中值为 20 [8; 32.5],放疗组为 10 [4; 18.5]。中位值与问卷中的 F、P 和 E 各部分之间无统计学差异(P=0.1585)。手术组和放疗组的发音障碍等级、粗糙度、呼吸困难、气喘和紧张量表的中位值分别为 2 [0; 5]和 2 [0.25; 3.75]。结论:我们的研究结果显示,手术组和放疗组之间没有明显差异(P=0.78):结论:我们的研究在嗓音障碍指数和等级、粗糙度、呼吸度、气喘和应变评分等主要终点上没有显示出任何显著差异:临床试验注册VOQUAL研究于2020年7月在ClinicalTrials.gov平台注册,注册号为NCT04447456。
{"title":"Voice quality after surgery or radiotherapy for glottic T1 squamous cell carcinoma: Results of the VOQUAL study","authors":"J. Louison ,&nbsp;J. Labreuche ,&nbsp;X. Liem ,&nbsp;B. Rysman ,&nbsp;M. Morisse ,&nbsp;G. Mortuaire ,&nbsp;F. Mouawad","doi":"10.1016/j.canrad.2024.03.004","DOIUrl":"10.1016/j.canrad.2024.03.004","url":null,"abstract":"<div><h3>Purpose</h3><p>Many series have compared voice quality after radiotherapy or surgery for cT1 glottic carcinoma. Different meta-analyses identify better results for radiotherapy while others do not identify any difference, some finally find a superiority of surgery. The purpose of this study was to compare the voice quality in the long term of patients who underwent transoral surgery versus exclusive irradiation for the treatment of cT1 glottic carcinoma.</p></div><div><h3>Material and methods</h3><p>The VOQUAL study was a pilot comparative multicenter cross-sectional study. The primary endpoint was the Voice Handicap Index comparison between two groups (radiotherapy or surgery). The voice assessment also consisted in the heteroevaluation of voice quality by the Grade, Roughness, Breathness, Asthenia, and Strain rating scale reported by Hirano.</p></div><div><h3>Results</h3><p>The study included 41 adult patients with cT1 carcinoma of the vocal cord treated by cordectomy or exclusive radiation in two oncologic centers. The median Voice Handicap Index value was 20 [8; 32.5] in the surgery group and 10 [4; 18.5] in the radiotherapy group. There was no statistically significant difference between the median values and the various components F, P and E of the questionnaire (<em>P</em> <!-->=<!--> <!-->0.1585). The median value of the numeric dysphonia Grade, Roughness, Breathness, Asthenia, and Strain scale was 2 [0; 5] in the surgery group and 2 [0.25; 3.75] in the radiotherapy group. There was no statistically significant difference between these values (<em>P</em> <!-->=<!--> <!-->0.78).</p></div><div><h3>Conclusion</h3><p>Our study did not show any significant difference on the primary endpoints of Voice Handicap Index and Grade, Roughness, Breathness, Asthenia, and Strain scores.</p></div><div><h3>Level of evidence</h3><p>III. Clinical trial registration: The VOQUAL study was registered on the ClinicalTrials.gov platform under the number <span><span>NCT04447456</span><svg><path></path></svg></span>, in July 2020.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 4","pages":"Pages 373-379"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Automatic segmentation of high-risk clinical target volume and organs at risk in brachytherapy of cervical cancer with a convolutional neural network 利用卷积神经网络自动分割宫颈癌近距离治疗中的高危临床靶区和危险器官
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1016/j.canrad.2024.03.002
J. Zhu , J. Yan , J. Zhang , L. Yu , A. Song , Z. Zheng , Y. Chen , S. Wang , Q. Chen , Z. Liu , F. Zhang

Purpose

This study aimed to design an autodelineation model based on convolutional neural networks for generating high-risk clinical target volumes and organs at risk in image-guided adaptive brachytherapy for cervical cancer.

Materials and methods

A novel SERes-u-net was trained and tested using CT scans from 98 patients with locally advanced cervical cancer who underwent image-guided adaptive brachytherapy. The Dice similarity coefficient, 95th percentile Hausdorff distance, and clinical assessment were used for evaluation.

Results

The mean Dice similarity coefficients of our model were 80.8%, 91.9%, 85.2%, 60.4%, and 82.8% for the high-risk clinical target volumes, bladder, rectum, sigmoid, and bowel loops, respectively. The corresponding 95th percentile Hausdorff distances were 5.23 mm, 4.75 mm, 4.06 mm, 30.0 mm, and 20.5 mm. The evaluation results revealed that 99.3% of the convolutional neural networks-generated high-risk clinical target volumes slices were acceptable for oncologist A and 100% for oncologist B. Most segmentations of the organs at risk were clinically acceptable, except for the 25% sigmoid, which required significant revision in the opinion of oncologist A. There was a significant difference in the clinical evaluation of convolutional neural networks-generated high-risk clinical target volumes between the two oncologists (P < 0.001), whereas the score differences of the organs at risk were not significant between the two oncologists. In the consistency evaluation, a large discrepancy was observed between senior and junior clinicians. About 40% of SERes-u-net-generated contours were thought to be better by junior clinicians.

Conclusion

The high-risk clinical target volumes and organs at risk of cervical cancer generated by the proposed convolutional neural networks model can be used clinically, potentially improving segmentation consistency and efficiency of contouring in image-guided adaptive brachytherapy workflow.

目的:本研究旨在设计一种基于卷积神经网络的自动划线模型,用于生成宫颈癌图像引导自适应近距离治疗中的高风险临床靶体积和高风险器官:使用 98 例接受图像引导自适应近距离治疗的局部晚期宫颈癌患者的 CT 扫描结果,对新型 SERes-u-net 进行了训练和测试。使用 Dice 相似性系数、第 95 百分位数 Hausdorff 距离和临床评估进行评估:在高风险临床靶体积、膀胱、直肠、乙状结肠和肠套叠方面,我们模型的平均 Dice 相似系数分别为 80.8%、91.9%、85.2%、60.4% 和 82.8%。相应的第 95 百分位数豪斯多夫距离分别为 5.23 毫米、4.75 毫米、4.06 毫米、30.0 毫米和 20.5 毫米。评估结果显示,肿瘤学家 A 和肿瘤学家 B 分别认为卷积神经网络生成的高风险临床目标容积切片的 99.3% 和 100%是可接受的,大多数高风险器官的分割在临床上是可接受的,只有 25% 的乙状结肠在肿瘤学家 A 看来需要进行重大修改:由所提出的卷积神经网络模型生成的宫颈癌高危临床靶体积和高危器官可用于临床,有可能提高图像引导自适应近距离治疗工作流程中分割的一致性和轮廓塑造的效率。
{"title":"Automatic segmentation of high-risk clinical target volume and organs at risk in brachytherapy of cervical cancer with a convolutional neural network","authors":"J. Zhu ,&nbsp;J. Yan ,&nbsp;J. Zhang ,&nbsp;L. Yu ,&nbsp;A. Song ,&nbsp;Z. Zheng ,&nbsp;Y. Chen ,&nbsp;S. Wang ,&nbsp;Q. Chen ,&nbsp;Z. Liu ,&nbsp;F. Zhang","doi":"10.1016/j.canrad.2024.03.002","DOIUrl":"10.1016/j.canrad.2024.03.002","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to design an autodelineation model based on convolutional neural networks for generating high-risk clinical target volumes and organs at risk in image-guided adaptive brachytherapy for cervical cancer.</p></div><div><h3>Materials and methods</h3><p>A novel SERes-u-net was trained and tested using CT scans from 98 patients with locally advanced cervical cancer who underwent image-guided adaptive brachytherapy. The Dice similarity coefficient, 95th percentile Hausdorff distance, and clinical assessment were used for evaluation.</p></div><div><h3>Results</h3><p>The mean Dice similarity coefficients of our model were 80.8%, 91.9%, 85.2%, 60.4%, and 82.8% for the high-risk clinical target volumes, bladder, rectum, sigmoid, and bowel loops, respectively. The corresponding 95th percentile Hausdorff distances were 5.23<!--> <!-->mm, 4.75<!--> <!-->mm, 4.06<!--> <!-->mm, 30.0<!--> <!-->mm, and 20.5<!--> <!-->mm. The evaluation results revealed that 99.3% of the convolutional neural networks-generated high-risk clinical target volumes slices were acceptable for oncologist A and 100% for oncologist B. Most segmentations of the organs at risk were clinically acceptable, except for the 25% sigmoid, which required significant revision in the opinion of oncologist A. There was a significant difference in the clinical evaluation of convolutional neural networks-generated high-risk clinical target volumes between the two oncologists (<em>P</em> <!-->&lt;<!--> <!-->0.001), whereas the score differences of the organs at risk were not significant between the two oncologists. In the consistency evaluation, a large discrepancy was observed between senior and junior clinicians. About 40% of SERes-u-net-generated contours were thought to be better by junior clinicians.</p></div><div><h3>Conclusion</h3><p>The high-risk clinical target volumes and organs at risk of cervical cancer generated by the proposed convolutional neural networks model can be used clinically, potentially improving segmentation consistency and efficiency of contouring in image-guided adaptive brachytherapy workflow.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 4","pages":"Pages 354-364"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50 kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study Folfirinox "化疗联合 50kVp 接触式 X 射线近距离放射治疗和 "CAP50 "化放疗,旨在保留经选择的中远端 cT2-T3 直肠癌的器官:可行性研究。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1016/j.canrad.2024.02.003
D. Mitrea , N. Barbet , T. Pacé-Loscos , C. Scouarnec , S. Ben-Dhia , D. Baron , L. Mineur , L. Évesque , J. Durand-Labrunie , J.-P. Gérard , G. Baudin , J. Doyen
<div><h3>Purpose</h3><p>The standard treatment of T2–T3 rectal adenocarcinoma is radical proctectomy by total mesorectal excision often combined with some neoadjuvant treatment. To reduce morbidity of this surgery, organ preservation strategy using various combination of radiotherapy, chemotherapy and local excision is gaining interest. Some randomized trials have proven the feasibility of such approaches. The OPERA trial demonstrated, for T2 T3<!--> <!--><<!--> <!-->5<!--> <!-->cm diameter low-middle rectum, that a contact X-ray brachytherapy boost of 90<!--> <!-->Gy in three fractions over 4 weeks was able to achieve a planned organ preservation in 81% of patients at 3<!--> <!-->years with 97% success for tumour smaller than 3<!--> <!-->cm treated with contact X-ray brachytherapy boost first. To try to expand organ preservation to larger tumours we set up a feasibility trial in T2–T3 tumours using total neoadjuvant treatment and a contact X-ray brachytherapy boost.</p></div><div><h3>Material and method</h3><p>The trial was approved by the institutional review board of Nice. Inclusion criteria were operable patients, 75<!--> <!-->years or less, adenocarcinoma of the low-middle rectum staged T2c-T3N0 larger than 3.5<!--> <!-->cm and less than 6<!--> <!-->cm in diameter or T2-T3N1 less than 6<!--> <!-->cm in diameter. Treatment started in all cases with neoadjuvant chemotherapy associating 5-fluoro-uracile, irinotecan and oxaliplatin (‘folfirinox’ regimen, four to six cycles). In case of good tumour response after four cycles, a contact X-ray brachytherapy boost (delivering 90<!--> <!-->Gy in three fractions) was given followed by chemoradiotherapy (external beam radiotherapy delivering 50<!--> <!-->Gy, with concurrent capecitabine). After six cycles if only a partial response (tumour still larger than 3<!--> <!-->cm) was seen, chemoradiotherapy was given and contact X-ray brachytherapy boost was delivered after that. At the end of this total neoadjuvant treatment a watch and wait strategy was decided in case of clinical complete response or radical proctectomy by total mesorectal excision for partial response.</p></div><div><h3>Results</h3><p>Between July 2019 and October 2022, 14 patients were included; median age was 66<!--> <!-->years (range: 51–77<!--> <!-->years), there were nine male and five female, two T2 N1 tumours, seven T3N0, and five T3N1, all were M0. Median tumour diameter was 40<!--> <!-->mm (range: 11–50<!--> <!-->mm); three tumours had a circumferential extension greater than 50%. Seven patients received four folfirinox cycles and seven had six cycles. Contact X-ray brachytherapy boost was given during folfirinox chemotherapy before chemoradiotherapy in 11 patients (and after in three). The tolerance was good, with no grade 4–5 toxicity. The main grade 3 early toxicity was in relation with the folfirinox regimen. A clinical complete response was seen in 12 patients at the end of the total neoadjuvant treatment (85%). All these
目的:T2-T3 直肠腺癌的标准治疗方法是直肠根治术,即全直肠中胚层切除术,通常结合一些新辅助治疗。为了降低这种手术的发病率,采用各种放疗、化疗和局部切除相结合的器官保留策略越来越受到关注。一些随机试验已经证明了这些方法的可行性。OPERA 试验证明了 T2 T3材料和方法的可行性:该试验获得了尼斯机构审查委员会的批准。纳入标准为可手术患者,75 岁或以下,直肠中下段腺癌分期为 T2c-T3N0 直径大于 3.5 厘米且小于 6 厘米或 T2-T3N1 直径小于 6 厘米。所有病例均开始接受新辅助化疗,包括 5-氟脲嘧啶、伊立替康和奥沙利铂("folfirinox "方案,4 至 6 个周期)。如果四个周期后肿瘤反应良好,则进行接触式 X 射线近距离放射治疗(分三次放疗,每次 90Gy),然后进行化放疗(体外放射治疗,每次 50Gy,同时使用卡培他滨)。六个周期后,如果仅出现部分反应(肿瘤仍大于 3 厘米),则进行化放疗,之后再进行接触式 X 射线近距离放射治疗。在整个新辅助治疗结束后,如果出现临床完全反应,则决定采取观察和等待策略;如果出现部分反应,则采取根治性直肠切除术,进行全直肠系膜切除:2019年7月至2022年10月期间,共纳入14例患者;中位年龄为66岁(范围:51-77岁),其中男性9例,女性5例,2例T2 N1肿瘤,7例T3N0,5例T3N1,均为M0。肿瘤直径中位数为40毫米(范围:11-50毫米);3个肿瘤的周缘扩展超过50%。七名患者接受了四个周期的枸橼酸雌二醇治疗,七名患者接受了六个周期的枸橼酸雌二醇治疗。11名患者在化疗前接受了枸橼酸化疗,3名患者在化疗后接受了接触式X射线近距离放射治疗。耐受性良好,没有出现 4-5 级毒性。3级早期毒性主要与枸橼酸化疗方案有关。在整个新辅助治疗结束时,有12名患者(85%)获得了临床完全反应。所有这些患者都还活着,并保留了直肠,平均随访时间为 17.8 个月(6-48 个月),肠道功能良好(直肠前切除综合征评分低于 30 分)。三名患者的主要接触性 X 射线近距离放射治疗毒性是放射溃疡,通常在 6 个月内愈合,有时需要高压氧治疗:结论:这项可行性研究的初步结果表明,新辅助治疗的早期耐受性与可接受的毒性是一致的。令人鼓舞的是,T2-T3肿瘤中间组的器官保留率很高,这为启动下一项随机TRESOR试验提供了很好的论据,该试验的目标是使中间肿瘤组的器官保留率达到65%,3年生存率达到65%。
{"title":"‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50 kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study","authors":"D. Mitrea ,&nbsp;N. Barbet ,&nbsp;T. Pacé-Loscos ,&nbsp;C. Scouarnec ,&nbsp;S. Ben-Dhia ,&nbsp;D. Baron ,&nbsp;L. Mineur ,&nbsp;L. Évesque ,&nbsp;J. Durand-Labrunie ,&nbsp;J.-P. Gérard ,&nbsp;G. Baudin ,&nbsp;J. Doyen","doi":"10.1016/j.canrad.2024.02.003","DOIUrl":"10.1016/j.canrad.2024.02.003","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;p&gt;The standard treatment of T2–T3 rectal adenocarcinoma is radical proctectomy by total mesorectal excision often combined with some neoadjuvant treatment. To reduce morbidity of this surgery, organ preservation strategy using various combination of radiotherapy, chemotherapy and local excision is gaining interest. Some randomized trials have proven the feasibility of such approaches. The OPERA trial demonstrated, for T2 T3&lt;!--&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;5&lt;!--&gt; &lt;!--&gt;cm diameter low-middle rectum, that a contact X-ray brachytherapy boost of 90&lt;!--&gt; &lt;!--&gt;Gy in three fractions over 4 weeks was able to achieve a planned organ preservation in 81% of patients at 3&lt;!--&gt; &lt;!--&gt;years with 97% success for tumour smaller than 3&lt;!--&gt; &lt;!--&gt;cm treated with contact X-ray brachytherapy boost first. To try to expand organ preservation to larger tumours we set up a feasibility trial in T2–T3 tumours using total neoadjuvant treatment and a contact X-ray brachytherapy boost.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and method&lt;/h3&gt;&lt;p&gt;The trial was approved by the institutional review board of Nice. Inclusion criteria were operable patients, 75&lt;!--&gt; &lt;!--&gt;years or less, adenocarcinoma of the low-middle rectum staged T2c-T3N0 larger than 3.5&lt;!--&gt; &lt;!--&gt;cm and less than 6&lt;!--&gt; &lt;!--&gt;cm in diameter or T2-T3N1 less than 6&lt;!--&gt; &lt;!--&gt;cm in diameter. Treatment started in all cases with neoadjuvant chemotherapy associating 5-fluoro-uracile, irinotecan and oxaliplatin (‘folfirinox’ regimen, four to six cycles). In case of good tumour response after four cycles, a contact X-ray brachytherapy boost (delivering 90&lt;!--&gt; &lt;!--&gt;Gy in three fractions) was given followed by chemoradiotherapy (external beam radiotherapy delivering 50&lt;!--&gt; &lt;!--&gt;Gy, with concurrent capecitabine). After six cycles if only a partial response (tumour still larger than 3&lt;!--&gt; &lt;!--&gt;cm) was seen, chemoradiotherapy was given and contact X-ray brachytherapy boost was delivered after that. At the end of this total neoadjuvant treatment a watch and wait strategy was decided in case of clinical complete response or radical proctectomy by total mesorectal excision for partial response.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Between July 2019 and October 2022, 14 patients were included; median age was 66&lt;!--&gt; &lt;!--&gt;years (range: 51–77&lt;!--&gt; &lt;!--&gt;years), there were nine male and five female, two T2 N1 tumours, seven T3N0, and five T3N1, all were M0. Median tumour diameter was 40&lt;!--&gt; &lt;!--&gt;mm (range: 11–50&lt;!--&gt; &lt;!--&gt;mm); three tumours had a circumferential extension greater than 50%. Seven patients received four folfirinox cycles and seven had six cycles. Contact X-ray brachytherapy boost was given during folfirinox chemotherapy before chemoradiotherapy in 11 patients (and after in three). The tolerance was good, with no grade 4–5 toxicity. The main grade 3 early toxicity was in relation with the folfirinox regimen. A clinical complete response was seen in 12 patients at the end of the total neoadjuvant treatment (85%). All these","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 4","pages":"Pages 323-332"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multicriteria optimization of radiation therapy: Towards empowerment and standardization of reverse planning for head and neck squamous cell carcinoma 放射治疗的多标准优化:实现头颈部鳞状细胞癌逆向计划的授权和标准化。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1016/j.canrad.2024.01.003

Purpose

The purpose of this study was to assess if multicriteria optimization could limit interoperator variability in radiation therapy planning and assess if this method could contribute to target volume coverage and sparing of organ at risk for intensity-modulated curative radiation therapy of head and neck cancers.

Material and methods

We performed a retrospective analysis on 20 patients treated for an oropharyngeal or oral cavity squamous cell carcinoma. We carried out a comparative dosimetric study of manual plans produced with Precision® software, compared with the plans proposed using the multicriteria optimization method (RayStation®). We assessed interoperator reproducibility on the first six patients, and dosimetric contribution in sparing organs at risk using the multicriteria optimization method.

Results

Median age was 69 years, most lesions were oropharyngeal carcinoma (65%), and 35% lesions were stage T3. First, we obtained a high degree of similarity between the four operator measurements for each patient at the level of each organ. Intraclass correlation coefficients were greater than 0.85. Second, we observed a significant dosimetric benefit for contralateral parotid gland, homolateral and contralateral masseter muscles, homolateral and contralateral pterygoid muscles and for the larynx (P < 0.05). For the contralateral parotid gland, the mean dose difference between the multicriteria optimization and manual plans was −2.0 Gy (P = 0.01). Regarding the larynx, the mean dose difference between the two plans was −4.6 Gy (P < 0.001).

Conclusion

Multicriteria optimization is a reproducible technique and faster than manual optimization. It allows dosimetric advantages on organs at risk, especially for those not usually taken into consideration in manual dosimetry. This may lead to improved quality of life.

目的:本研究的目的是评估多标准优化是否能限制放疗计划中操作者之间的差异,并评估这种方法是否有助于头颈部癌症的强度调控根治性放疗的靶体积覆盖和危险器官的保护:我们对 20 名接受口咽或口腔鳞状细胞癌治疗的患者进行了回顾性分析。我们对使用 Precision® 软件制作的手动计划与使用多标准优化方法 (RayStation®) 提出的计划进行了剂量测定比较研究。我们对前六名患者的操作员之间的可重复性进行了评估,并使用多标准优化法评估了放射剂量对保留危险器官的贡献:中位年龄为 69 岁,大多数病灶为口咽癌(65%),35% 的病灶为 T3 期。首先,在每个器官层面上,我们对每位患者的四个操作者测量结果之间具有高度的相似性。类内相关系数大于 0.85。其次,我们观察到对侧腮腺、同侧和对侧的颌下肌、同侧和对侧的翼状肌以及喉部(PC结论:多标准优化是一种有效的治疗方法:多标准优化是一种可重复的技术,比人工优化更快。它能对有风险的器官进行剂量测定,尤其是对人工剂量测定通常不考虑的器官进行剂量测定。这可能会提高生活质量。
{"title":"Multicriteria optimization of radiation therapy: Towards empowerment and standardization of reverse planning for head and neck squamous cell carcinoma","authors":"","doi":"10.1016/j.canrad.2024.01.003","DOIUrl":"10.1016/j.canrad.2024.01.003","url":null,"abstract":"<div><h3>Purpose</h3><p>The purpose of this study was to assess if multicriteria optimization could limit interoperator variability in radiation therapy planning and assess if this method could contribute to target volume coverage and sparing of organ at risk for intensity-modulated curative radiation therapy of head and neck cancers.</p></div><div><h3>Material and methods</h3><p>We performed a retrospective analysis on 20 patients treated for an oropharyngeal or oral cavity squamous cell carcinoma. We carried out a comparative dosimetric study of manual plans produced with Precision® software, compared with the plans proposed using the multicriteria optimization method (RayStation®). We assessed interoperator reproducibility on the first six patients, and dosimetric contribution in sparing organs at risk using the multicriteria optimization method.</p></div><div><h3>Results</h3><p><span>Median age was 69 years, most lesions were oropharyngeal carcinoma (65%), and 35% lesions were stage T3. First, we obtained a high degree of similarity between the four operator measurements for each patient at the level of each organ. Intraclass correlation coefficients were greater than 0.85. Second, we observed a significant dosimetric benefit for contralateral parotid gland, homolateral and contralateral masseter muscles, homolateral and contralateral pterygoid muscles and for the larynx (</span><em>P</em> <!-->&lt;<!--> <!-->0.05). For the contralateral parotid gland, the mean dose difference between the multicriteria optimization and manual plans was −2.0<!--> <!-->Gy (<em>P</em> <!-->=<!--> <!-->0.01). Regarding the larynx, the mean dose difference between the two plans was −4.6<!--> <!-->Gy (<em>P</em> <!-->&lt;<!--> <!-->0.001).</p></div><div><h3>Conclusion</h3><p>Multicriteria optimization is a reproducible technique and faster than manual optimization. It allows dosimetric advantages on organs at risk, especially for those not usually taken into consideration in manual dosimetry. This may lead to improved quality of life.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 4","pages":"Pages 317-322"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep learning applied to dose prediction in external radiation therapy: A narrative review 深度学习应用于体外放射治疗的剂量预测:综述。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1016/j.canrad.2024.03.005
V. Lagedamon, P.-E. Leni, R. Gschwind

Over the last decades, the use of artificial intelligence, machine learning and deep learning in medical fields has skyrocketed. Well known for their results in segmentation, motion management and posttreatment outcome tasks, investigations of machine learning and deep learning models as fast dose calculation or quality assurance tools have been present since 2000. The main motivation for this increasing research and interest in artificial intelligence, machine learning and deep learning is the enhancement of treatment workflows, specifically dosimetry and quality assurance accuracy and time points, which remain important time-consuming aspects of clinical patient management. Since 2014, the evolution of models and architectures for dose calculation has been related to innovations and interest in the theory of information research with pronounced improvements in architecture design. The use of knowledge-based approaches to patient-specific methods has also considerably improved the accuracy of dose predictions. This paper covers the state of all known deep learning architectures and models applied to external radiotherapy with a description of each architecture, followed by a discussion on the performance and future of deep learning predictive models in external radiotherapy.

过去几十年来,人工智能、机器学习和深度学习在医疗领域的应用急剧增加。机器学习和深度学习模型因其在分割、运动管理和治疗后结果任务方面的成果而闻名,自 2000 年以来,作为快速剂量计算或质量保证工具的机器学习和深度学习模型的研究一直存在。对人工智能、机器学习和深度学习的研究和兴趣与日俱增的主要动机是加强治疗工作流程,特别是剂量测定和质量保证的准确性和时间点,这仍然是临床患者管理的重要耗时方面。自 2014 年以来,剂量计算模型和架构的演变与信息研究理论的创新和兴趣有关,架构设计有了明显改善。基于知识的患者特定方法的使用也大大提高了剂量预测的准确性。本文介绍了应用于体外放射治疗的所有已知深度学习架构和模型的现状,并对每种架构进行了描述,随后讨论了深度学习预测模型在体外放射治疗中的性能和前景。
{"title":"Deep learning applied to dose prediction in external radiation therapy: A narrative review","authors":"V. Lagedamon,&nbsp;P.-E. Leni,&nbsp;R. Gschwind","doi":"10.1016/j.canrad.2024.03.005","DOIUrl":"10.1016/j.canrad.2024.03.005","url":null,"abstract":"<div><p>Over the last decades, the use of artificial intelligence, machine learning and deep learning in medical fields has skyrocketed. Well known for their results in segmentation, motion management and posttreatment outcome tasks, investigations of machine learning and deep learning models as fast dose calculation or quality assurance tools have been present since 2000. The main motivation for this increasing research and interest in artificial intelligence, machine learning and deep learning is the enhancement of treatment workflows, specifically dosimetry and quality assurance accuracy and time points, which remain important time-consuming aspects of clinical patient management. Since 2014, the evolution of models and architectures for dose calculation has been related to innovations and interest in the theory of information research with pronounced improvements in architecture design. The use of knowledge-based approaches to patient-specific methods has also considerably improved the accuracy of dose predictions. This paper covers the state of all known deep learning architectures and models applied to external radiotherapy with a description of each architecture, followed by a discussion on the performance and future of deep learning predictive models in external radiotherapy.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 4","pages":"Pages 402-414"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141977501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of MRI-based radiomics in predicting pathological complete response to neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A narrative review 基于磁共振成像的放射组学在预测局部晚期直肠癌新辅助化放疗病理完全反应中的意义:综述。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1016/j.canrad.2024.04.003
Y. Li, X. Liu, M. Gu, T. Xu, C. Ge, P. Chang

Neoadjuvant chemoradiotherapy is the standard treatment for patients with locally advanced rectal cancers owing to its ability to downstage primary tumours. Some patients can achieve pathological complete response after neoadjuvant therapy, and can adopt a “watch and wait” treatment strategy to avoid overtreatment. Therefore, it is essential to develop strategies for predicting responses to neoadjuvant therapy. Radiomics has shown great potential in extracting tumour features from high-throughput medical images for the construction of mathematics models for predicting the effects of anticancerous therapies. Herein, we explored MRI-based radiomics and found that it can predict responses of locally advanced rectal cancers to chemoradiation. Efficient radiomics model allow early-stage prediction of the effect of neoadjuvant chemoradiotherapy on locally advanced rectal cancers. It helps clinicians to make informed therapeutic decisions. In this review, we discuss the workflow of radiomics, and summarize the clinical application of MRI-based radiomics in predicting pathological complete response to neoadjuvant chemoradiotherapy of locally advanced rectal cancer.

由于新辅助化放疗能够降低原发肿瘤的分期,因此是局部晚期直肠癌患者的标准治疗方法。一些患者在接受新辅助治疗后可获得病理完全反应,并可采取 "观察和等待 "的治疗策略,以避免过度治疗。因此,制定预测新辅助治疗反应的策略至关重要。放射组学在从高通量医学影像中提取肿瘤特征以构建用于预测抗癌疗法效果的数学模型方面显示出巨大的潜力。在此,我们探索了基于核磁共振成像的放射组学,发现它可以预测局部晚期直肠癌对化疗的反应。高效的放射组学模型可以在早期预测新辅助化放疗对局部晚期直肠癌的影响。这有助于临床医生做出明智的治疗决策。在这篇综述中,我们讨论了放射组学的工作流程,并总结了基于磁共振成像的放射组学在预测局部晚期直肠癌新辅助化放疗病理完全反应方面的临床应用。
{"title":"Significance of MRI-based radiomics in predicting pathological complete response to neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A narrative review","authors":"Y. Li,&nbsp;X. Liu,&nbsp;M. Gu,&nbsp;T. Xu,&nbsp;C. Ge,&nbsp;P. Chang","doi":"10.1016/j.canrad.2024.04.003","DOIUrl":"10.1016/j.canrad.2024.04.003","url":null,"abstract":"<div><p>Neoadjuvant chemoradiotherapy is the standard treatment for patients with locally advanced rectal cancers owing to its ability to downstage primary tumours. Some patients can achieve pathological complete response after neoadjuvant therapy, and can adopt a “watch and wait” treatment strategy to avoid overtreatment. Therefore, it is essential to develop strategies for predicting responses to neoadjuvant therapy. Radiomics has shown great potential in extracting tumour features from high-throughput medical images for the construction of mathematics models for predicting the effects of anticancerous therapies. Herein, we explored MRI-based radiomics and found that it can predict responses of locally advanced rectal cancers to chemoradiation. Efficient radiomics model allow early-stage prediction of the effect of neoadjuvant chemoradiotherapy on locally advanced rectal cancers. It helps clinicians to make informed therapeutic decisions. In this review, we discuss the workflow of radiomics, and summarize the clinical application of MRI-based radiomics in predicting pathological complete response to neoadjuvant chemoradiotherapy of locally advanced rectal cancer.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 4","pages":"Pages 390-401"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1278321824000970/pdfft?md5=ce9f489cf0df1fa38d458f01be574ced&pid=1-s2.0-S1278321824000970-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142038010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy for central neurocytoma: A multicentric retrospective study in France 中枢神经细胞瘤的放射治疗:法国的一项多中心回顾性研究。
IF 1.5 4区 医学 Q4 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.1016/j.canrad.2024.03.003
Guillaume Virbel , Charles-Henry Mallereau , Benoît Lhermitte , Loïc Feuvret , Julian Biau , Laurie Clément , Cédric Khoury , Valérie Bernier , Nicolas Milhade , Ronan Tanguy , Philippe Colin , Hélène Cébula , François Proust , Luc Bauchet , Georges Noël

Purpose

Neurocytomas represent 0.25 to 0.5% of primary brain tumours and are mainly found in young adults. These tumours have neuronal differentiation. The cornerstone treatment is neurosurgery. The efficacy of other therapies, including radiotherapy, is still unclear. The objective of this study was to evaluate the management of central neurocytomas and the role of radiotherapy.

Materials and methods

All adult patients (age 18 years or older) newly diagnosed with a histologically confirmed neurocytoma between 2006 and 2015 in France were included.

Results

One hundred and sixteen patients were diagnosed with a central neurocytoma during the study period. All patients underwent surgical resection, and six received adjuvant radiotherapy. Eleven patients received radiotherapy due to progression. After a median follow-up of 68.7 months, local failure occurred in 29 patients. The 5-year local control rate was 73.4%. According to univariate analysis, marker of proliferation Ki67 index greater than 2% (hazard ratio [HR]: 1.48; confidence interval [CI]: 1.40–1.57; P = 0.027) and subtotal resection (HR: 8.48; CI: 8.01–8.99; P < 0.001) were associated with an increase in local failure. Gross total resection was associated with a higher risk of sequelae epilepsy (HR: 3.62; CI: 3.42–3.83; P < 0.01) and memory disorders (HR: 1.35; CI: 1.07–1.20; P < 0.01). Ten patients (8.6%) died during the follow-up. The 10-year overall survival rate was 89.0%. No prognostic factors for overall survival were found.

Conclusion

The analysis showed that patients who underwent subtotal surgical resection, particularly when the tumour had a Ki67 index greater than 2%, had an increased risk of local recurrence. These patients could benefit from adjuvant radiotherapy.

目的:神经细胞瘤占原发性脑肿瘤的 0.25%至 0.5%,主要见于青壮年。这些肿瘤具有神经元分化。治疗的基础是神经外科手术。包括放射治疗在内的其他疗法的疗效尚不明确。本研究旨在评估中枢神经细胞瘤的治疗方法和放射治疗的作用:纳入2006年至2015年期间法国所有新诊断出组织学确诊神经细胞瘤的成年患者(18岁或以上):结果:研究期间有116名患者被诊断为中枢神经细胞瘤。所有患者均接受了手术切除,其中六名患者接受了辅助放疗。11名患者因病情进展接受了放疗。中位随访 68.7 个月后,29 名患者出现局部治疗失败。5年局部控制率为73.4%。单变量分析显示,增殖标志物 Ki67 指数大于 2%(危险比 [HR]:1.48;置信区间 [CI]:1.40-1.57;P=0.027)和次全切除(HR:8.48;CI:8.01-8.99;PConclusion:分析表明,接受次全切除手术的患者,尤其是当肿瘤的Ki67指数大于2%时,局部复发的风险会增加。这些患者可从辅助放疗中获益。
{"title":"Radiotherapy for central neurocytoma: A multicentric retrospective study in France","authors":"Guillaume Virbel ,&nbsp;Charles-Henry Mallereau ,&nbsp;Benoît Lhermitte ,&nbsp;Loïc Feuvret ,&nbsp;Julian Biau ,&nbsp;Laurie Clément ,&nbsp;Cédric Khoury ,&nbsp;Valérie Bernier ,&nbsp;Nicolas Milhade ,&nbsp;Ronan Tanguy ,&nbsp;Philippe Colin ,&nbsp;Hélène Cébula ,&nbsp;François Proust ,&nbsp;Luc Bauchet ,&nbsp;Georges Noël","doi":"10.1016/j.canrad.2024.03.003","DOIUrl":"10.1016/j.canrad.2024.03.003","url":null,"abstract":"<div><h3>Purpose</h3><p>Neurocytomas represent 0.25 to 0.5% of primary brain tumours and are mainly found in young adults. These tumours have neuronal differentiation. The cornerstone treatment is neurosurgery. The efficacy of other therapies, including radiotherapy, is still unclear. The objective of this study was to evaluate the management of central neurocytomas and the role of radiotherapy.</p></div><div><h3>Materials and methods</h3><p>All adult patients (age 18 years or older) newly diagnosed with a histologically confirmed neurocytoma between 2006 and 2015 in France were included.</p></div><div><h3>Results</h3><p>One hundred and sixteen patients were diagnosed with a central neurocytoma during the study period. All patients underwent surgical resection, and six received adjuvant radiotherapy. Eleven patients received radiotherapy due to progression. After a median follow-up of 68.7 months, local failure occurred in 29 patients. The 5-year local control rate was 73.4%. According to univariate analysis, marker of proliferation Ki67 index greater than 2% (hazard ratio [HR]: 1.48; confidence interval [CI]: 1.40–1.57; <em>P</em> <!-->=<!--> <!-->0.027) and subtotal resection (HR: 8.48; CI: 8.01–8.99; <em>P</em> <!-->&lt;<!--> <!-->0.001) were associated with an increase in local failure. Gross total resection was associated with a higher risk of sequelae epilepsy (HR: 3.62; CI: 3.42–3.83; <em>P</em> <!-->&lt;<!--> <!-->0.01) and memory disorders (HR: 1.35; CI: 1.07–1.20; <em>P</em> <!-->&lt;<!--> <!-->0.01). Ten patients (8.6%) died during the follow-up. The 10-year overall survival rate was 89.0%. No prognostic factors for overall survival were found.</p></div><div><h3>Conclusion</h3><p>The analysis showed that patients who underwent subtotal surgical resection, particularly when the tumour had a Ki67 index greater than 2%, had an increased risk of local recurrence. These patients could benefit from adjuvant radiotherapy.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 4","pages":"Pages 365-372"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Radiotherapie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1